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Background: Deep infection following endoprosthetic limb reconstruction for sarcoma of the long bones is a
devastating complication occurring in 15% of sarcoma patients. Optimizing infection protocols and conducting
definitive surgical trials are critical to improving outcomes. In this study, the PARITY (Prophylactic Antibiotic
Regimens in Tumor Surgery) investigators aimed to examine surgeon preferences in antibiotic prophylaxis and
perceptions about current evidence, as well as to ascertain interest in resolving uncertainty in the evidence with
clinical trials.
Methods: We used a cross-sectional survey to examine current practice in the prescription of prophylactic
antibiotics in Musculoskeletal Tumor Surgery. The survey was approved by our institution’s Ethics Board and
emailed to all Active Members of the Musculoskeletal Tumor Society (MSTS) and Canadian Orthopaedic Oncology
Society (CANOOS). Survey answers were collected using an anonymous online survey tool.
Results: Of the 96 surgeons who received the questionnaire, 72 responded (75% response rate (% CI: 65.5, 82.5%)).
While almost all respondents agreed antibiotic regimens were important in reducing the risk of infection,
respondents varied considerably in their choices of antibiotic regimens and dosages. Although 73% (95% CI: 61,
82%) of respondents prescribe a first generation cephalosporin, 25% favor additional coverage with an
aminoglycoside and/or Vancomycin. Of those who prescribe a cephalosporin, 33% prescribe a dosage of one gram
for all patients and the reminder prescribe up to 2 grams based on body weight. One in three surgeons (95% CI:
25, 48%) believes antibiotics could be discontinued after 24 hours but 40% (95% CI: 30, 53%) continue antibiotics
until the suction drain is removed. Given the ongoing uncertainty in evidence to guide best practices, 90% (95% CI:
81, 95%) of respondents agreed that they would change their practice if a large randomized controlled trial showed
clear benefit of an antibiotic drug regimen different from what they are currently using. Further support for a
clinical trial was observed by an overwhelming surgeon interest (87%; 95% CI: 77, 93%) in participating in a
multi-center randomized controlled study.
Conclusion: The current lack of guidelines for the prescription of prophylactic antibiotics in Musculoskeletal Tumor
Surgery has left Orthopaedic Oncologists with varying opinions and practices. The lack of current evidence and
strong surgeon support for participating in a definitive study provides strong rationale for clinical trials.* Correspondence: khaled.hasan@medportal.ca
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Table 1 Physician demographics
Characteristic No. (%)




Over 60 8 (11.1%)




Over 20 26 (36.6%)
Type of Hospital Academic 62 (86.1%)
Non-Academic 10 (13.9%)






Proportion of practice with





Number of long bone







> 25 13 (18.6%)
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Limb salvage surgery is the standard of care for the vast
majority of patients with long-bone sarcoma such as
Ewing’s Sarcoma and Osteosarcoma [1]. Limb-salvage re-
construction techniques generally involve replacement of
the affected bone segment and joint with a prosthetic im-
plant designed to recreate the normal anatomy. Preserva-
tion of neurovascular structures and the need to avoid
tumor contamination of the wound result in lengthy,
complicated procedures. In addition, many patients re-
quire pre- and post-operative chemotherapy for systemic
disease management. These factors result in a high inci-
dence of deep post-operative infections (15%–30%) requir-
ing surgical intervention and eventual limb-salvage failure
(amputation) in approximately 50% of cases [2-6].
The high infection rates have been stable over the past 2
decades [2,3,5,7]. The standard guidelines for antibiotic
prophylaxis as dictated by the American Academy of
Orthopaedic Surgeons (AAOS) for total joint replace-
ments includes a pre-operative dose of antibiotics with
gram-positive coverage followed by 24 hours of post-
operative antibiotics [7,8]. In fact, the only dose that has
been shown to be important in preventing post-operative
infections is the pre-operative dose [7,9,10].
In higher-risk cases of tumor prosthesis surgery, no
guidelines exist to direct antibiotic management. In fact,
many tumor surgeons prescribe several days of antibiotics
and add gram-negative coverage. However, there is no
data to support these practices and the issue of antibiotic
resistance with over-prescription therefore becomes im-
portant. There has been a clear link between antibiotic
overprescription and the emergence of resistant microbial
organisms [8,9,11].
To explore current practice in the regimens of anti-
biotic prophylaxis used for tumor surgery, we conducted
an international survey of practicing orthopaedic oncol-
ogy surgeons in order to learn about their preferences
with regards to this practice and to identify the need for
future research in this area. Furthermore, we reasoned
that the results of this survey may identify factors that
influence a surgeon's preference for a particular regimen,
serve to educate the orthopaedic community on issues
regarding prosthesis infection, and allow for the develop-
ment of future clinically related trials, which could help
develop an international guideline for prophylactic anti-




We developed a questionnaire using focus groups, key
informants, and the previous literature.
The items generated from the focus group were
improved by data from a MEDLINE search of articlespublished from 1975 to 2011 using text words "infection,"
"sarcoma," "surgery," and “antibacterial agents”. Further
items were generated with key informants. Surgeons spe-
cializing in orthopaedic oncology provided additional in-
put into potential items for the questionnaire.Pretesting and validity assessments
In order to accurately address the need for antibiotic
prophylaxis guidelines in tumour prosthesis surgery, the
questionnaire was pretested amongst an independent
group of four orthopaedic oncologists (face validity) with
respect to reconstruction type, antibiotics used, and time
points and dosages administered (content validity). These
surgeons also commented on the clarity and comprehen-
siveness of the questionnaire.
The questionnaire itself consisted four sections, and
presented closed-ended questions as multiple-choice or
five-point Likert scale formats. Section A encompasses
Table 2 Effectiveness of antimicrobial coverage relative to gram positive coverage alone in reducing infection risk in
long-bone reconstruction














Gram+and Gram - coverage 2 (3.0%) 2 (3.0%) 33 (50.0%) 23 (34.8%) 6 (9.1%)
Gram - coverage alone 40 (60.6%) 16 (24.2%) 10 (15.2%) 0 (0.0%) 0 (0.0%)
Vancomycin 3 (4.6%) 6 (9.2%) 31 (47.7%) 22 (33.8%) 3 (4.6%)
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gender, years in practice, type of practice [academic versus
community setting], fellowship training in orthopaedic on-
cology, and supervision of resident trainees) and surgical
volume. Section B sought information regarding surgeons’
management of oncology cases - specifically with regards
to how long after chemotherapy can surgery be safely per-
formed, at what white blood cell count the patient is safe
for surgery. Section C consists of nine questions that ad-
dress features of a particular surgeon’s antibiotic regimen
(i.e. reconstruction type, specific antibiotics used, time
period [pre- and/or post-operatively] and dosages admi-
nistered). Section D addresses the need for future research
in this area and provides participants with an opportunity
to offer comments and/or suggestions.Questionnaire administration
All Active Members of the Musculoskeletal Tumor Soci-
ety (MSTS) and all members of the Canadian Ortho-
paedic Oncology Society (CANOOS) (duplicates were
excluded) were surveyed voluntarily via a web-based
method (Survey Monkey). Potential participants were
sent the survey by a party independent of the study’s
investigators, with no monetary incentives. One e-mail
pre-notification was provided. All response data was col-
lected anonymously and grouped according to pre-
defined analyses. The Ethics Review Board in conjunc-
tion with Hamilton Health Sciences approved this study.
No monetary incentives or pre-notification telephone
calls were used for this survey. Individual responses were
kept confidential and questionnaire completion was
voluntary.Sample size
We had a response rate goal of 70% to ensure the results
would be adequately powered to prevent the biased as-
certainment of outcomes due to non-responder bias [12-Table 3 Length of time prophylactic antibiotics prescribed fo
Type of Reconstruction 24 hours 48 hou
Tumor prosthesis 25 (35.7%) 13 (18.
Allograft 18 (26.5%) 13 (19.
Allograft-prosthesis composite 17 (25.4%) 12 (17.14]. To determine the number of respondents needed to
sufficiently power our analysis, we assumed that ap-
proximately 40% of surgeons surveyed used prophylactic
antibiotics until the suction drain is removed for long-
bone reconstruction postoperatively. Using the following
formula:
N ¼ ðz2  ðp 1−pð Þ=w2
N ¼ 1:962  0:4  0:6 =0:052
N ¼ 368:8
Where:
N= required sample size
Z= z value (1.96 for 95% confidence interval)
w= the confidence interval, expressed as
decimal (0.05 = +/− 5)
p= percentage picking a choice (until suction drain
removed), expressed in decimal (40%= 0.40)
It was calculated that 369 completed questionnaires
would be required to produce a 95% confidence interval
(CI) of +/− 5% around the percentages of postoperative
prescription of prophylactic antibiotics until suction
drain is removed, with an alpha level of 0.05. A total of
96 surgeons were approached to participate. The re-
sponse rate was 75% (95% CI: 66%, 84%). The sample size
of 72 completed survey allowed a 95% CI of +/− 12%
around the percentages of the use prophylactic antibiotic
until suction drain is removed for long-bone reconstruc-
tion postoperatively.
Statistical analysis
A previous report has shown that closed-ended ques-
tions result in fewer incomplete questionnaires than
open-ended formats [15]. The current questionnaire
framed the response options in one of two ways: five-
point Likert scales or nominal scales. The proportion ofllowing long-bone reconstruction
rs 3–7 days Until suction drain is removed
6%) 3 (4.3%) 29 (41.4%)
1%) 11 (16.2%) 26 (38.2%)
9%) 9 (13.4%) 29 (43.3%)
Table 4 Dosage of Ancef (first generation cephalosporin)
prescribed (if applicable)
Dosage No. (%)
1 g 9 (12.9%)
2 g 23 (32.9%)
2 g only if patient >80 kg 37 (52.9%)
N/A 1 (1.4%)
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confidence intervals (CI) using Wilson’s exact method
were calculated.
Results
Characteristics of the respondents
Of the 96 surgeons who received the questionnaire, 72
(75%; 95% CI: 65.5, 82.5%) responded. The typical re-
spondent was a surgeon over 40 yrs old with over 5 yrs
in practice (Table 1). The majority (86.1%) work in an
academic centre and supervise trainees (90%)] (Table 1).
Ninety-seven percent of respondents had completed fur-
ther orthopaedic oncology fellowship training and 70%
of respondents spend greater than 50% of their practice
treating orthopaedic oncology patients (Table 1).
Management preferences
Over 90 % (95% CI: 90, 99%) of respondents believe that
prophylactic antibiotic protocols are important to de-
crease the risk of infection in all long bone sarcoma re-
construction types. Forty-six percent (95% CI: 35, 57%)
believe that preoperative antibiotic administration is the
single most important initial step to preventing post-
operative infection while 50% (95% CI: 38, 61%) believe
that both preoperative and post-operative antibiotic ad-
ministration are important to prevent postoperative
infection.
Antibiotic regimens
Seventy-three percent (95% CI: 61, 82%) of respondents
routinely prescribe gram-positive coverage alone for long
bone reconstruction while 11% prescribe gram positive
and gram negative coverage. Four percent (95% CI: 1,
12%) of respondents prescribe Vancomycin alone. When
comparing regimens to gram positive coverage alone,
50% (95% CI: 38, 62%) responded it would be equivalent
to a combination of gram positive and gram negative
prophylaxis (Table 2).
Duration of antibiotics
Thirty-six percent (95% CI: 25, 48%) of respondents
practice discontinuing antibiotics after 24 hrs and 18%
(95% CI:11, 29%) discontinue at 48 hours. However 41%
(95% CI: 30, 53%) continue antibiotics until the suction
drain is removed (Table 3). Forty-three percent (95% CI:
32, 55%) of respondents believe that there is currently
no evidence to guide surgeons regarding the optimal
antibiotic prophylaxis in long-bone reconstruction.
First generation cephalosporin dosing
Thirteen percent (95% CI: 7, 23%) of surgeons
responded to prescribing one gram of Ancef (Cefazolin)
per dose, while 33% (95% CI: 23, 44%) prescribe two
grams of Ancef per dose (Table 4). Another 53% (95%CI: 41, 64%) responded that they prescribe two grams of
Ancef per dose if the patient weighed greater than 80 kg
(Table 4).
Need for further research
There was a considerable amount of support among
respondents for further research including strong support
for a large clinical trial to evaluate outcomes following dif-
ferent prophylactic antibiotic regimens. Specifically 84%
(95% CI: 73, 91%) felt there was a need for further trials to
evaluate outcomes following different prophylactic anti-
biotic drugs (Table 5). Eighty-three percent (95% CI: 73,
91%) felt there is a need for further trials to evaluate out-
comes following different prophylactic antibiotic regimens
(Table 5). An overwhelming 90% (95% CI: 81, 95%) of
respondents would change their practice if a large rando-
mized controlled trial showed clear benefit of an antibiotic
drug and regimen different from what they currently pre-
scribe (Table 6) and 87% (95% CI: 77, 93%) of respondents
agreed they would participate in a large randomized con-
trol trial. The majority of respondents feel that as little as
a 10% absolute risk reduction in infection would be a clin-
ically significant benefit (Table 6).
Discussion
The results of this survey demonstrated five key findings.
(1) Surgeons vary considerably in their choices of anti-
biotic regimens and dosages demonstrating a lack of
consensus on which prophylactic antibiotic regimen is
believed to be most effective. (2) The duration of pre-
scribed regimen varies between surgeons as well with
one in three surgeons believing antibiotics could be dis-
continued after 24 hours while 40% continue antibiotics
until the suction drain is removed. (3) Surgeons also felt
there was a lack of evidence and uncertainty with regard
to which prescription of antibiotic regimen was most ef-
fective. (4) Respondents were overwhelmingly in favor of
a large multi-center randomized control trial to assess
the efficacy of different regimens. (5) More significantly
ninety percent of surgeons agreed that they would change
their practice if a large randomized controlled trial showed
clear benefit of an antibiotic drug regimen different from
what they are currently using with the majority of Ortho-
paedic Oncology Surgeons considering a 10% absolute risk
reduction in infection rates to be clinically significant.
Table 5 Need for further research
Strongly agree Agree Unsure Disagree Strongly disagree
I feel there is a need for further trials to evaluate
outcomes following different prophylactic antibiotic drugs
30 (43.5%) 28 (40.6%) 5 (7.2%) 3 (4.3%) 3 (4.3%)
I feel there is a need for further trials to evaluate
outcomes following different prophylactic antibiotic regimens
32 (46.4%) 26 (37.7%) 5 (7.2%) 4 (5.8%) 2 (2.9%)
I feel there is a need for studies on the cost-effectiveness
of different antibiotic drugs and regimens
18 (26.1%) 28 (40.6%) 11 (15.9%) 5 (7.2%) 7 (10.1%)
I would change my practice if a large randomized
controlled trial showed clear benefit of an antibiotic drug
and regimen different from what I am currently using
51 (72.9%) 12 (17.1%) 3 (4.3%) 1 (1.4%) 3 (4.3%)
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guidelines directing the prescription of prophylactic anti-
biotic regimens in musculoskeletal tumor surgery. With
the emergence of resistant antimicrobial organisms and
outbreaks of clostridium difficile in healthcare facilities,
duration and prescription of antibiotics has proven to be
an important clinical entity. At the same time, a high in-
fection rate of 15-30% reported in many studies [2-6]
highlights the importance of optimizing antibiotic regi-
mens. There is no doubt that the development of clinical
guidelines is of paramount and immediate importance.
Due to the fact that bone sarcomas are rare, a rando-
mized clinical trial designed to create high level evidence
would require multi-institutional and likely international
participation. To date, this type of study has not been
attempted in the Orthopaedic Oncology community.
However, such a study is possible with support from a
Surgical Trials Methods Center which exists at the insti-
tution of the primary authors for this study. A trial has
been designed and is under funding and ethics review,
which will involve randomizing patients undergoing
lower extremity tumor prosthesis reconstruction to ei-
ther 24 hours or 5 days of cephalosporin coverage. TheTable 6 Clinical importance and interest in participating stud
Any red
Amount an alternative antibiotic drug
and regimen needs to reduce infection












I would participate in a multi-centre
randomized controlled study assessing
different antibiotic regimens in long-bone
reconstruction for tumor surgery.
Yes
Nostudy will be double-blinded as randomization will be
completed by the Pharmacy Department at each institu-
tion. Thus, with completion of this study, there is the
possibility that eventually guidelines such as those pro-
vided by the AAOS will be created for this very challen-
ging peri-operative issue in Orthopaedic Oncology.
The strengths of our study include obtaining a compre-
hensive sampling of North American orthopaedic oncology
surgeons from both the Canadian Orthopaedic Oncology
Society (CANOOS) and Musculoskeletal Tumor Society
(MSTS), achieving an exceptional survey response rate
of approximately 75% that helps to limit non-responder
bias with active surgeon participation along with a compre-
hensive sampling of surgeons from academic and non-
academic centres,
Our response rate of 75% of Orthoepdic Oncologists
provided a robust data set for the general purposes of our
study as well as exceeded the level for our anticipated
study precision. Nevertheless, future studies that are
aimed at more rigorously evaluating potential sampling-
bias will include surgeons from Europe and Asia. While
non-responeder bias could not be eliminated it was mini-
mized through re-administering the survey specifically toy
No. (%)
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Conclusion
We have shown that there are varied opinions and varia-
tions from surgeons on the prescription of prophylactic
antibiotic regimens in tumor surgery. There is as yet no
clinical trial on the efficacy of different antibiotic regi-
mens in preventing infection in long-bone prosthetic re-
construction. However, there is overwhelming support in
the Orthopaedic Oncology community to participate in
a multi-center trial, which is currently in the state of
development.
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